Molecular Investigation of the Antitumor Effects of Monoamine Oxidase Inhibitors in Breast Cancer Cells.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
09
2022
revised:
05
09
2023
accepted:
19
09
2023
medline:
23
10
2023
pubmed:
16
10
2023
entrez:
16
10
2023
Statut:
epublish
Résumé
The catalytic activity of monoamine oxidase A (MAO-A) has been linked to tumorigenesis due to the production of reactive oxygen species (ROS) and the resulting oxidative stress. MAO-A inhibition revealed a beneficial role in prostate and lung cancer treatment. This study is aimed at evaluating the effect of different monoamine oxidase A inhibitors (MAO-AIs) on the proliferation and progression of breast cancer cell lines. The cell viability assay was used to evaluate the antiproliferative and combined effects of MAO-AIs. Cell migration was evaluated using wound healing, invasion, and colony formation assays. The underlying mechanism of cell death was studied using flow cytometry. The real-time polymerase chain reaction was used to determine the relative gene expression. Finally, MAO-A activity in breast cancer cells was evaluated using an MAO-A activity assay. According to the results, the examined MAO-AIs significantly inhibited the proliferation of breast cancer cells in a dose-dependent manner. In breast cancer cells, the combination of anticancer drugs (doxorubicin or raloxifene) with MAO-AIs resulted in a synergistic effect. MAO-AIs significantly reduced wound closure and invasion ability in breast cancer cells. Also, MAO-AIs reduced the colony count and size of breast cancer cells. MAO-AIs resulted in significant proapoptotic activity in breast cancer cells. Finally, the MAO-AIs suppressed
Identifiants
pubmed: 37841082
doi: 10.1155/2023/2592691
pmc: PMC10569896
doi:
Substances chimiques
Monoamine Oxidase Inhibitors
0
Monoamine Oxidase
EC 1.4.3.4
Reactive Oxygen Species
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2592691Informations de copyright
Copyright © 2023 Aseel Alkhawaldeh and Sanaa Bardaweel.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Cancer Med. 2020 Nov;9(21):8004-8019
pubmed: 32931665
Oncogene. 2018 Sep;37(38):5175-5190
pubmed: 29844571
Prostate. 2019 May;79(6):667-677
pubmed: 30693539
Anticancer Agents Med Chem. 2022;22(18):3114-3124
pubmed: 35473535
Cell Signal. 2014 Dec;26(12):2621-32
pubmed: 25152370
J Clin Invest. 2014 Jul;124(7):2891-908
pubmed: 24865426
Cell Mol Biol Lett. 2019 Nov 12;24:59
pubmed: 31754354
Cold Spring Harb Perspect Med. 2016 Mar 01;6(3):a026104
pubmed: 26931810
Hypertension. 2013 Jul;62(1):140-6
pubmed: 23670301
Curr Med Chem. 2009;16(25):3267-85
pubmed: 19548866
J Hepatol. 2014 Jun;60(6):1225-34
pubmed: 24607627
Sci Rep. 2019 Jul 29;9(1):10989
pubmed: 31358840
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:102-11
pubmed: 24104186
Eurasian J Med. 2018 Oct;50(3):193-201
pubmed: 30515042
J Neural Transm (Vienna). 2018 Nov;125(11):1553-1566
pubmed: 30259128
Int J Biol Sci. 2020 Aug 1;16(14):2692-2703
pubmed: 32792865
J Pathol. 2017 Oct;243(2):220-229
pubmed: 28722111
Int J Mol Sci. 2017 Dec 20;18(12):
pubmed: 29261141
Tumour Biol. 2014 Nov;35(11):10635-44
pubmed: 25238879
Expert Opin Ther Targets. 2017 Oct;21(10):959-966
pubmed: 28831824
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Pharmaceutics. 2011 Mar 11;3(1):107-24
pubmed: 24310428
Acta Pharm. 2020 Jun 1;70(2):179-190
pubmed: 31955147
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jul 1;44:118-24
pubmed: 23410524
Molecules. 2020 Dec 25;26(1):
pubmed: 33375766
Antimicrob Agents Chemother. 2012 Mar;56(3):1508-15
pubmed: 22203607
Molecules. 2022 Apr 30;27(9):
pubmed: 35566238
Nat Clin Pract Oncol. 2007 Mar;4(3):181-9
pubmed: 17327858
Molecules. 2021 Oct 04;26(19):
pubmed: 34641563
BMC Med Genomics. 2009 Aug 20;2:55
pubmed: 19691856
Curr Opin Pharmacol. 2017 Apr;33:64-69
pubmed: 28528298
Molecules. 2020 May 11;25(9):
pubmed: 32403270
J Mol Cell Cardiol. 2014 Aug;73:34-42
pubmed: 24412580
J Urol. 2008 Nov;180(5):2206-11
pubmed: 18804811
Cancer Res. 1996 May 1;56(9):2013-6
pubmed: 8616842
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
BMC Complement Altern Med. 2014 Aug 12;14:297
pubmed: 25112895
Oncol Lett. 2018 Mar;15(3):3245-3251
pubmed: 29435065
Adv Hematol. 2012;2012:524308
pubmed: 21941553
Nat Commun. 2020 Jun 1;11(1):2689
pubmed: 32483206
Oncotarget. 2016 Mar 22;7(12):13842-53
pubmed: 26871599
PLoS One. 2014 Sep 08;9(9):e104271
pubmed: 25198178
Int J Breast Cancer. 2011;2011:967419
pubmed: 22332018
Sci Rep. 2016 Feb 24;6:21986
pubmed: 26906215